Home News
Tirzepatide News
Pricing changes, regulatory decisions, coverage shifts and consumer alerts — dated, sourced, and written to say what each one changes for a patient.
This section tracks what changes what you pay for tirzepatide and what you can get: manufacturer price changes, FDA and state regulatory action, coverage decisions, market exits and documented consumer-harm patterns. Every item is dated to the development, not to when we wrote it.
Most recent: We re-checked fifteen compounded prices at source. Fourteen were wrong (2026-08-05).
Browse by category
Every story, newest first
We re-checked fifteen compounded prices at source. Fourteen were wrong
Every correction moved the price upward, which means published 'cheapest' figures across this category are systematically low.
Embody suspended from our rankings after a documented service-failure pattern
Recent one-star reviews describe payment taken without shipment, unreachable support and unpaid refunds. It held our cheapest tracked price.
Fewer than a fifth of priced programs will name the pharmacy that makes your medicine
We scored every tracked programme on what it publishes before you pay. The results are worse than the marketing suggests.
Delivery complaints at Oak Longevity, the cheapest tracked program
Non-delivery, postal routing and summer heat exposure appear in the negative reviews of a program holding our lowest verified price. It does not meet our suspension threshold.
Who actually makes your medicine: three ownership structures, three risk profiles
Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when something goes wrong.
Summer shipping is the season for cold-chain failures
Warm arrivals cluster in the hottest months, and most programs put the judgement call on the patient.
Medicare GLP-1 Bridge begins dispensing at $50 a month
Eligible Part D beneficiaries pay a flat $50 for certain weight-management GLP-1s regardless of dose, under a pilot running to the end of 2027.
Compounded GLP-1 access consolidates toward smaller operators
As the large consumer platforms exit, the cheap end of the market is increasingly served by companies most patients have never heard of.
Microdose protocols spread, and they are not comparable to standard dosing
Several programs now sell fractional-dose plans at lower prices. They do not map onto the 2.5–15 mg ladder every comparison uses.
FDA proposes excluding semaglutide and tirzepatide from the 503B bulks list
If finalised, outsourcing facilities would lose a pathway for compounding these molecules at scale.
Membership stacking spreads: the advertised price is increasingly not the price
Several programs now split the charge into medication plus a mandatory platform fee, which most comparison tables do not add back.
More employers drop weight-management GLP-1 coverage at plan renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.
Oral GLP-1 readouts land below injectable tirzepatide on effect size
Convenience and price improve; magnitude does not match the injectable head-to-head.
Alerts continue on counterfeit brand product and research-labelled peptide
Two different problems, one outcome: an unverified substance in a syringe.
Washington State acts against a telehealth company's own compounding pharmacy
When the platform and the pharmacy are the same business, a state action against one is an action against your prescription.
First-month promotional rates are being published as ongoing prices
A recurring error across round-ups, and the likely origin of several of the wrong figures we corrected.
First oral GLP-1 for weight loss approved, priced from $149
An oral small-molecule agent reaches the market at a fraction of injectable brand pricing, with a smaller effect size.
States gain the option to expand GLP-1 access through Medicaid
A route that did not exist for the lowest-income patients — but it is optional, so it will be a patchwork.
State exclusion lists keep moving, and programs rarely announce it
Availability is set programme by programme and changes without notice — including after you have enrolled.
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest telehealth platforms exits compounded semaglutide, leaving brand-only access.
Mounjaro joins LillyDirect self-pay at 50–60% below list
The diabetes-labelled tirzepatide gets a cash channel, which changes the calculation for anyone with a type 2 diabetes diagnosis.
Zepbound KwikPen reaches self-pay pricing and national pharmacy pickup
The multi-dose pen joins the vial at $299–$449, and Lilly extends self-pay pickup beyond its own channel.
Lilly cuts Zepbound self-pay vial pricing to $299–$449
The starter dose drops from $349 to $299 and the 5 mg vial from $499 to $399, with everything above 7.5 mg at $449 on a 45-day refill condition.
FDA issues warning letters to compounded GLP-1 telehealth marketers
MEDVi, Ivim Health and the operator of SkinnyRx were among those cited on 20 February 2026 over labelling and marketing claims.
Prepaid plans are where the money gets stuck
Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once shipped.
A year after the shortage was declared over, the compounded market has restructured
Scope narrowed, large platforms exited, and pricing moved — but patient-specific compounding continues.
SURMOUNT-5 puts tirzepatide 20.2% against semaglutide 13.7%
The only randomised head-to-head between the two molecules, and the number every comparison since has leaned on.
Withdrawal data reframe tirzepatide as maintenance therapy, not a course
Participants moved to placebo regained substantially; those who continued held or kept losing.
Zepbound approved for obstructive sleep apnoea in adults with obesity
The first drug approved for moderate-to-severe OSA in this population — and a route to coverage that a BMI threshold does not open.
What we cover and what we do not
We cover things that change what a patient pays, what they can get, or what they should check: manufacturer pricing changes, FDA and state regulatory action, coverage decisions, market exits and documented consumer-harm patterns. We do not cover funding rounds, celebrity use, or study press releases that have not produced a published paper.
Every item carries the date of the development rather than the date we published it, names its source, and ends with what it changes. Where a story is still moving — a proposed rule, an ongoing enforcement matter — the item says so rather than implying it is settled.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.